The firm sells a rapid, point-of-care, PCR platform for infectious disease diagnostics, including SARS-CoV-2, influenza, respiratory syncytial virus, and Strep A.
The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.
The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.
Genetworx and PacificDx's tests detect SARS-CoV-2 nucleic acid, while Hologic's test can also detect and differentiate SARS-CoV-2 and influenza A and B.
The panel simultaneously tests for SARS-CoV-2 and influenza viruses A and B, while a second analysis detects for human respiratory syncytial virus and human metapneumovirus.
The test kit, which provides results in under two hours, is PCR system-agnostic and is suitable for use with a range of instruments, according to the company.
The PCR test detects SARS-CoV-2, influenza A/B, and respiratory syncytial virus type A and B and runs on the Elite InGenius platform and other major thermcyclers.
